These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 36853837)

  • 1. A Monoclonal Antibody That Provides a Model for C3 Nephritic Factors.
    Hourcade DE; Mitchell LM
    Monoclon Antib Immunodiagn Immunother; 2023 Feb; 42(1):9-14. PubMed ID: 36853837
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel Assays to Distinguish Between Properdin-Dependent and Properdin-Independent C3 Nephritic Factors Provide Insight Into Properdin-Inhibiting Therapy.
    Michels MAHM; van de Kar NCAJ; van den Bos RM; van der Velden TJAM; van Kraaij SAW; Sarlea SA; Gracchi V; Oosterveld MJS; Volokhina EB; van den Heuvel LPWJ
    Front Immunol; 2019; 10():1350. PubMed ID: 31263464
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Unraveling the Molecular Mechanisms Underlying Complement Dysregulation by Nephritic Factors in C3G and IC-MPGN.
    Donadelli R; Pulieri P; Piras R; Iatropoulos P; Valoti E; Benigni A; Remuzzi G; Noris M
    Front Immunol; 2018; 9():2329. PubMed ID: 30487789
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Different Aspects of Classical Pathway Overactivation in Patients With C3 Glomerulopathy and Immune Complex-Mediated Membranoproliferative Glomerulonephritis.
    Michels MAHM; van de Kar NCAJ; van Kraaij SAW; Sarlea SA; Gracchi V; Engels FAPT; Dorresteijn EM; van der Deure J; Duineveld C; Wetzels JFM; van den Heuvel LPWJ; Volokhina EB
    Front Immunol; 2021; 12():715704. PubMed ID: 34456924
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Two types of C3 nephritic factor: properdin-dependent C3NeF and properdin-independent C3NeF.
    Tanuma Y; Ohi H; Hatano M
    Clin Immunol Immunopathol; 1990 Aug; 56(2):226-38. PubMed ID: 2143128
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sensitive and specific assays for C3 nephritic factors clarify mechanisms underlying complement dysregulation.
    Paixão-Cavalcante D; López-Trascasa M; Skattum L; Giclas PC; Goodship TH; de Córdoba SR; Truedsson L; Morgan BP; Harris CL
    Kidney Int; 2012 Nov; 82(10):1084-92. PubMed ID: 22854646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modeling C3 glomerulopathies: C3 convertase regulation on an extracellular matrix surface.
    Pisarenka S; Meyer NC; Xiao X; Goodfellow R; Nester CM; Zhang Y; Smith RJH
    Front Immunol; 2022; 13():1073802. PubMed ID: 36846022
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum properdin consumption as a biomarker of C5 convertase dysregulation in C3 glomerulopathy.
    Corvillo F; Bravo García-Morato M; Nozal P; Garrido S; Tortajada A; Rodríguez de Córdoba S; López-Trascasa M
    Clin Exp Immunol; 2016 Apr; 184(1):118-25. PubMed ID: 26660535
    [TBL] [Abstract][Full Text] [Related]  

  • 9. C5 nephritic factors drive the biological phenotype of C3 glomerulopathies.
    Marinozzi MC; Chauvet S; Le Quintrec M; Mignotet M; Petitprez F; Legendre C; Cailliez M; Deschenes G; Fischbach M; Karras A; Nobili F; Pietrement C; Dragon-Durey MA; Fakhouri F; Roumenina LT; Fremeaux-Bacchi V
    Kidney Int; 2017 Nov; 92(5):1232-1241. PubMed ID: 28712854
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overactivity of Alternative Pathway Convertases in Patients With Complement-Mediated Renal Diseases.
    Michels MAHM; van de Kar NCAJ; Okrój M; Blom AM; van Kraaij SAW; Volokhina EB; van den Heuvel LPWJ
    Front Immunol; 2018; 9():612. PubMed ID: 29670616
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Causes of alternative pathway dysregulation in dense deposit disease.
    Zhang Y; Meyer NC; Wang K; Nishimura C; Frees K; Jones M; Katz LM; Sethi S; Smith RJ
    Clin J Am Soc Nephrol; 2012 Feb; 7(2):265-74. PubMed ID: 22223606
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protection of the classical and alternative complement pathway C3 convertases, stabilized by nephritic factors, from decay by the human C3b receptor.
    Fischer E; Kazatchkine MD; Mecarelli-Halbwachs L
    Eur J Immunol; 1984 Dec; 14(12):1111-4. PubMed ID: 6240408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. C4 Nephritic Factors in C3 Glomerulopathy: A Case Series.
    Zhang Y; Meyer NC; Fervenza FC; Lau W; Keenan A; Cara-Fuentes G; Shao D; Akber A; Fremeaux-Bacchi V; Sethi S; Nester CM; Smith RJH
    Am J Kidney Dis; 2017 Dec; 70(6):834-843. PubMed ID: 28838767
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nephritic Factors: An Overview of Classification, Diagnostic Tools and Clinical Associations.
    Corvillo F; Okrój M; Nozal P; Melgosa M; Sánchez-Corral P; López-Trascasa M
    Front Immunol; 2019; 10():886. PubMed ID: 31068950
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of decay-accelerating factor on the assembly of the classical and alternative pathway C3 convertases in the presence of C4 or C3 nephritic factor.
    Ito S; Tamura N; Fujita T
    Immunology; 1989 Dec; 68(4):449-52. PubMed ID: 2481642
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Properdin- and nephritic factor-dependent C3 convertases: requirement of native C3 for enzyme formation and the function of bound C3b as properdin receptor.
    Schreiber RD; Medicus RG; Gïtze O; Müller-Eberhard HJ
    J Exp Med; 1975 Sep; 142(3):760-72. PubMed ID: 1165475
    [TBL] [Abstract][Full Text] [Related]  

  • 17. C3 nephritic factor (C3NeF): stabilization of fluid phase and cell-bound alternative pathway convertase.
    Daha MR; Fearon DT; Austen KF
    J Immunol; 1976 Jan; 116(1):1-7. PubMed ID: 1245733
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Production of nephritic factor of the alternative complement pathway by Epstein Barr virus-transformed B cell lines derived from a patient with membranoproliferative glomerulonephritis.
    Hiramatsu M; Balow JE; Tsokos GC
    J Immunol; 1986 Jun; 136(12):4451-5. PubMed ID: 3011894
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Testing the Activity of Complement Convertases in Serum/Plasma for Diagnosis of C4NeF-Mediated C3 Glomerulonephritis.
    Blom AM; Corvillo F; Magda M; Stasiłojć G; Nozal P; Pérez-Valdivia MÁ; Cabello-Chaves V; Rodríguez de Córdoba S; López-Trascasa M; Okrój M
    J Clin Immunol; 2016 Jul; 36(5):517-27. PubMed ID: 27146825
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insights into the Effects of Complement Factor H on the Assembly and Decay of the Alternative Pathway C3 Proconvertase and C3 Convertase.
    Bettoni S; Bresin E; Remuzzi G; Noris M; Donadelli R
    J Biol Chem; 2016 Apr; 291(15):8214-30. PubMed ID: 26903516
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.